Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Consulting agrmnt
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 8-K Quarterly results
Docs: "Corbus Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update • CRB-701 Phase 1 trial in China is ahead of schedule with dose escalation completion expected Q4 2023 and U.S. clinical trial start planned for Q1 2024 • Preliminary clinical PK data indicates CRB-701 has a longer half-life and reduced levels of circulating free MMAE relative to published data for PADCEV® • CRB-601 IND submission is on track for Q4 2023 Norwood, MA, August 8, 2023 -- Corbus Pharmaceuticals Holdings, Inc. , a precision oncology company, today provided a corporate update and reported financial results for the second quarter of 2023. “During the second quarter, substantial progress was made advancing CRB-701, our next generation Nectin-4 antibody dru..."
05/09/2023 8-K Quarterly results
Docs: "Corbus Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update • Company expanded precision oncology pipeline with in-licensing of CRB-701: a clinical-stage Nectin-4 antibody drug conjugate from CSPC Pharmaceutical Group • CRB-701 Phase 1 dose escalation study ongoing in patients with advanced solid tumors in China • Presented latest CRB-601 anti-αvβ8 mAb pre-clinical data at American Association of Cancer Research 2023 annual meeting with IND submission on track for the second half of 2023 • Expanded Board of Directors with appointment of Yong Ben, MD Norwood, MA, May 9, 2023 -- Corbus Pharmaceuticals Holdings, Inc. , a precision oncology company, today provided a corporate update and reported financial results for..."
03/07/2023 8-K Investor presentation, Quarterly results
Docs: "Corbus Pharmaceuticals Reports Fourth Quarter 2022 and Year-End Financial Results and Provides Corporate Update • Company expands precision oncology pipeline with licensing of CRB-701, clinical-stage Nectin-4 antibody drug conjugate from CSPC Pharmaceutical Group • CRB-701 Phase 1 dose escalation ongoing in China in patients with advanced solid tumors • CRB-601 anti-αvβ8 mAb program scheduled for IND submission in the second half of 2023 • CRB-601 continues to demonstrate compelling pre-clinical monotherapy and combination data with anti-PD-1 • Dr. Yong Ben, distinguished oncology researcher joins the Corbus Board of Directors Norwood, MA, March 7, 2023 -- Corbus Pharmaceuticals Holdings, Inc. , a precision oncology company, today provided a c...",
"BT8009 MOA ADC ADC BTC"
12/21/2022 8-K Quarterly results
08/09/2022 8-K Quarterly results
Docs: "Corbus Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update • Promising pre-clinical data generated for CRB-601 across several tumor models as monotherapy and in combination with anti-PD1 therapy • IND submission for CRB-601 is on track for mid-2023 • Expanding immuno-oncology pipeline through strategic transactions remains key priority • Cash and investments on hand of $74 million funds operations into the first quarter of 2024 Norwood, MA, August 9, 2022 -- Corbus Pharmaceuticals Holdings, Inc. , an immunology company, today provided a corporate update and reported financial results for the second quarter of 2022. Key Corporate and Program Updates: • Anti-integrin monoclonal antibody programs targeting the inhibiti..."
05/10/2022 8-K Quarterly results
03/08/2022 8-K Quarterly results
11/12/2021 8-K Quarterly results
Docs: "Corbus Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Updates  Company continues to advance integrin program from preclinical development toward the clinic  Expanding pipeline through strategic transactions remains key priority  Cash and investments on hand of $108 million sufficient to support execution of research, clinical and operational goals into the first quarter of 2024 Norwood, MA, November 12, 2021 -- Corbus Pharmaceuticals Holdings, Inc. , an immunology company, today provided corporate updates and reported financial results for the third quarter of 2021. Key Programs' Updates:  Anti-integrin monoclonal antibody program targeting solid tumors continues to advance toward the clinic with first patient dosed antic..."
05/13/2021 8-K Quarterly results
11/10/2020 8-K Investor presentation, Quarterly results
Docs: "Corbus Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Updates"
08/06/2020 8-K Quarterly results
05/11/2020 8-K Quarterly results
03/12/2020 8-K Quarterly results
11/07/2019 8-K Quarterly results
Docs: "Corbus Pharmaceuticals Reports 2019 Third Quarter Financial Results and Provides Clinical and Corporate Updates"
08/08/2019 8-K Quarterly results
Docs: "Corbus Pharmaceuticals Reports 2019 Second Quarter Financial Results and Provides Clinical and Corporate Updates"
05/09/2019 8-K Quarterly results
Docs: "Corbus Pharmaceuticals Reports 2019 First Quarter Financial Results and Provides Clinical Updates"
11/08/2018 8-K Quarterly results
Docs: "Corbus Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update"
08/08/2018 8-K Quarterly results
Docs: "Corbus Pharmaceuticals Reports 2018 Second Quarter Financial Results and Provides Business Update"
05/10/2018 8-K Quarterly results
Docs: "Corbus Pharmaceuticals Reports 2018 First Quarter Financial Results and Provides Business Update"
11/08/2017 8-K Quarterly results
Docs: "Corbus Pharmaceuticals Reports 2017 Third Quarter Financial Results and Highlights Recent Corporate and Clinical Advancements"
08/09/2017 8-K Quarterly results
Docs: "Corbus Pharmaceuticals Reports 2017 Second Quarter Financial Results and Provides Business Update"
05/09/2017 8-K Form 8-K - Current report
11/10/2016 8-K Form 8-K - Current report
08/15/2016 8-K Quarterly results
Docs: "Corbus Pharmaceuticals Reports 2016 Second Quarter Financial Results and Provides Business Update"
05/16/2016 8-K Quarterly results
Docs: "Corbus Pharmaceuticals Reports 2016 First Quarter Financial Results and Provides Business Update"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy